Skip to main content
Journal cover image

Cellular changes in eculizumab early responders with generalized myasthenia gravis.

Publication ,  Journal Article
Li, Y; Yi, JS; Howard, JF; Chopra, M; Russo, MA; Guptill, JT
Published in: Clin Immunol
October 2021

Eculizumab (ECU), a C5 complement inhibitor, is approved to treat acetylcholine receptor autoantibody positive generalized myasthenia gravis (AChR MG). The clinical effect of ECU relies on inhibition of the terminal complement complex; however, the effect of ECU on lymphocytes is largely unknown. We evaluated innate and adaptive immunity among AChR MG patients (N = 3) before ECU and ≥3 months later while on stable therapy, and found reduced activation markers in memory CD4+ T cell subsets, increased regulatory T cell populations, and reduced frequencies of CXCR5+HLA-DR+CCR7+ Tfh subsets and CD11b+ migratory memory B cells. We observed increases within CD8+ T cell subsets that were terminally differentiated and senescent. Our data suggest complement inhibition with ECU modulates the adaptive immunity in patients with MG, consistent with preclinical data showing changes in complement-mediated signaling by T- and antigen-presenting cells. These findings extend our understanding of ECU's mechanism of action when treating patients with MG.

Duke Scholars

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

October 2021

Volume

231

Start / End Page

108830

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Myasthenia Gravis
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Female
  • Complement Inactivating Agents
  • B-Lymphocytes
  • Antibodies, Monoclonal, Humanized
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, Y., Yi, J. S., Howard, J. F., Chopra, M., Russo, M. A., & Guptill, J. T. (2021). Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clin Immunol, 231, 108830. https://doi.org/10.1016/j.clim.2021.108830
Li, Yingkai, John S. Yi, James F. Howard, Manisha Chopra, Melissa A. Russo, and Jeffrey T. Guptill. “Cellular changes in eculizumab early responders with generalized myasthenia gravis.Clin Immunol 231 (October 2021): 108830. https://doi.org/10.1016/j.clim.2021.108830.
Li Y, Yi JS, Howard JF, Chopra M, Russo MA, Guptill JT. Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clin Immunol. 2021 Oct;231:108830.
Li, Yingkai, et al. “Cellular changes in eculizumab early responders with generalized myasthenia gravis.Clin Immunol, vol. 231, Oct. 2021, p. 108830. Pubmed, doi:10.1016/j.clim.2021.108830.
Li Y, Yi JS, Howard JF, Chopra M, Russo MA, Guptill JT. Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clin Immunol. 2021 Oct;231:108830.
Journal cover image

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

October 2021

Volume

231

Start / End Page

108830

Location

United States

Related Subject Headings

  • T-Lymphocytes
  • Myasthenia Gravis
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Female
  • Complement Inactivating Agents
  • B-Lymphocytes
  • Antibodies, Monoclonal, Humanized